Tripep signs a Letter of Intent with San Diego based Inovio Inc for a joint clinical development of ChronVac-B, a therapeutic vaccine for chronic hepatitis B virus infections

Tripep signs a Letter of Intent with San Diego based Inovio Inc for a joint
clinical development of ChronVac-B, a therapeutic vaccine for chronic hepatitis
B virus infections

Tripep and San Diego-based Inovio Inc have today signed a Letter of Intent for a
joint development of a therapeutic vaccine for chronic hepatitis B virus
infections. The companies already have an ongoing collaboration on the
ChronVac-C vaccine delivered using Inovio's DNA delivery technology for the
treatment of chronic infections caused by the hepatitis C virus, which this
month enters phase I/II clinical testing. 
The new collaborative project combines Tripep's ChronVac-B vaccine technology
and Inovio's in vivo electroporation technology. Almost a third of the world's
population has come into contact with the hepatitis B virus. It is estimated
that around 400 million are chronic carriers, with an elevated risk for severe
liver disease and cancer. Today's approved therapies have problems with side
effects and development of antiviral resistance. Thus, there is a great need to
improve therapies for chronic hepatitis B virus infections. A therapeutic
vaccine aims at improving the immune response of the infected patient by a
specific activation of the hepatitis B-specific immunity in order to help the
patient to gain control of the infection. At present only prophylactic vaccines
for hepatitis B infections are available. The combined market for the treatment
of chronic hepatitis B and C virus infections is estimated to 3,5 billion USD.

” I am very pleased to announce this new collaborative project with Inovio's
adding to Tripep's project portfolio. We already know that the combination of
Tripep's and Inovio's technologies work well together. We therefore expect that
this new joint project will reach the clinic rapidly” says Tripep's CEO Jan
Nilsson.

For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail:
jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail:
anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .